Navigation Links
Angiotech Pharmaceuticals announces FDA approval of TAXUS(R) Liberte(R) Long Stent
Date:7/16/2009

VANCOUVER, July 16 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) today announced that its corporate partner, Boston Scientific Corporation (NYSE: BSX) has received approval from the U.S. Food and Drug Administration (FDA) to market its TAXUS(R) Liberte(R) Long Paclitaxel-Eluting Coronary Stent System, a next-generation drug-eluting stent (DES) designed for long lesions. At 38 mm, it is the longest available DES, providing doctors an option that can potentially reduce the number of stents used in more complex cases, simplifying procedures and reducing costs. It affords a more efficient treatment option for the estimated 8 to 10 percent(1) of patients with long lesions. Boston Scientific plans to launch the product in the U.S. next month. It received CE Mark approval in 2007.

"The TAXUS Liberte Long Stent offers physicians and patients distinct advantages compared to using two overlapping drug-eluting stents," said Mark Turco, M.D., FACC, FSCAI, Director of the Center for Cardiac Vascular Research at Washington Adventist Hospital, Takoma Park, Maryland. "In the ATLAS Long Lesion Trial, the 38 mm TAXUS Liberte Stent significantly reduced myocardial infarction when compared to the TAXUS(R) Express(R) Stent, making the TAXUS Liberte Long Stent an attractive option for interventional cardiologists faced with long, challenging lesions."

The TAXUS ATLAS Long Lesion Trial reported a significant 79 percent reduction in the rate of nine-month myocardial infarction for the TAXUS Liberte Long Stent as compared to the TAXUS Express Stent control (1.3% vs. 6.3%, p=0.026). At two years, the composite measure of cardiac death or myocardial infarction showed a significant 63 percent reduction for the TAXUS Liberte Long Stent compared to
'/>"/>

SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Angiotech Pharmaceuticals, Inc. announces conference call and webcast
2. Angiotech Pharmaceuticals announces FDA 510(k) clearance of the Option(TM) Inferior Vena Cava Filter
3. Angiotech Enters License, Distribution and Supply Agreements for Fibrin and Thrombin Technologies with Haemacure Corporation
4. Angiotech Pharmaceuticals announces FDA approval of next-generation TAXUS(R) Liberte(R) Atom(TM) Stent system
5. Angiotechs corporate partner, Boston Scientific, announces launch of third-generation TAXUS(R) Element(TM) Stent
6. Angiotech launches e-commerce website that allows customers to order Quill(TM) SRS product line
7. Angiotech Pharmaceuticals, Inc. announces financial results for the first quarter ended March 31, 2009
8. Angiotech announces date of annual general meeting of shareholders
9. Angiotech Pharmaceuticals, Inc. Announces Conference Call And Webcast
10. Angiotech Pharmaceuticals, Inc. announces License Agreement with Baxter International Inc.
11. Angiotech announces positive results from Bio-Seal(TM) clinical study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... 31, 2014 Huge event with ... future pharma industry health, analysis and forecasting   ... the closing of its most successful show to date ... 2,500 exhibitors. Held this year in Paris ... key players from 140+ countries representing every step of ...
(Date:10/31/2014)... Jeffrey T. Manuel, assistant professor in Southern ... College of Arts and Sciences, is teaming up with ... alcohol-based fuels in Illinois. , “Farmers, researchers, ... to build Illinois’ biofuels industry for decades,” Manuel said. ... state's agricultural and business history. , “Fuel alcohol ...
(Date:10/31/2014)... ENVIRON , an international ... that Dr. Harvey Clewell III has rejoined the ... closely with senior professionals in ENVIRON’s Health Sciences ... at The Hamner Institutes for Health Sciences (The ... he is Director, Center for Human Health Assessment. ...
(Date:10/30/2014)... -- Investor-Edge has initiated coverage on the ... Inc. (NASDAQ: MDVN ), Pharmacyclics Inc. (NASDAQ: ... SYN), and Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD). Free research ... http://investor-edge.com/register . On Wednesday, October 29, 2014, ... Dow Jones Industrial Average declined 0.18%, to finish the ...
Breaking Biology Technology:CPhI Worldwide 2014 Announces Biggest Ever Show and Points to Pharma Growth in Brazil, Russia and Fast Emerging Africa 2CPhI Worldwide 2014 Announces Biggest Ever Show and Points to Pharma Growth in Brazil, Russia and Fast Emerging Africa 3CPhI Worldwide 2014 Announces Biggest Ever Show and Points to Pharma Growth in Brazil, Russia and Fast Emerging Africa 4CPhI Worldwide 2014 Announces Biggest Ever Show and Points to Pharma Growth in Brazil, Russia and Fast Emerging Africa 5CPhI Worldwide 2014 Announces Biggest Ever Show and Points to Pharma Growth in Brazil, Russia and Fast Emerging Africa 6SIUE History Prof Manuel Working on Biofuels Book with NCERC 2SIUE History Prof Manuel Working on Biofuels Book with NCERC 3Internationally recognized health scientist Dr. Harvey Clewell renews association with ENVIRON 2Internationally recognized health scientist Dr. Harvey Clewell renews association with ENVIRON 3Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 2Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 3Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 4Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 5
... March 16, Shire plc (LSE: SHP, NASDAQ: ... the U.S. District Court of the Southern District of,New ... three,of Shire,s patents: U.S. Patent No. 5,968,976 (",976 Patent"); ... (",465"). , The lawsuit was ...
... AutoImmune Inc. (OTC Bulletin Board: AIMM) today reported a net ... for the three months ended December 31, 2008, compared with ... basic and diluted, for the three months ended December 31, ... loss was $345,000, or $0.02 per share basic and diluted, ...
... 16 Contamination by mycoplasmal organisms is an ... them ready sources of contamination, while rendering them ... white paper, examines how PCR mycoplasma tests ... minimizes testing delays and enable safe, high-volume biopharmaceutical ...
Cached Biology Technology:Shire Files Lawsuit Against Barr Laboratories for Infringement of FOSRENOL(R) (Lanthanum Carbonate) Patents 2AutoImmune Inc. Reports 2008 Fourth Quarter and Year End Financial Results 2AutoImmune Inc. Reports 2008 Fourth Quarter and Year End Financial Results 3AutoImmune Inc. Reports 2008 Fourth Quarter and Year End Financial Results 4New White Paper Examines Advanced Mycoplasma Tests - How Real-Time PCR Analysis Helps Save Time and Money for Biopharmaceutical Manufacturers 2New White Paper Examines Advanced Mycoplasma Tests - How Real-Time PCR Analysis Helps Save Time and Money for Biopharmaceutical Manufacturers 3
(Date:10/29/2014)... At a ceremony held in New York City on ... King, the American Cancer Society Professor of Genome Sciences ... and 2008 Honorary Doctor of Philosophy of Tel Aviv ... in Medical Science. , In addition to her honorary ... Lecturer at the TAU School of Medicine, and for ...
(Date:10/29/2014)... One kind of stem cell, those referred to as ... There is apparently nothing that differentiates these cells from ... namely they retain the capacity to become stem cells ... liver, an organ that hosts cells that stimulate tissue ... the case of a transplant. Knowledge of the ...
(Date:10/29/2014)... in the living world compete with members of ... how much they invest into their competitive ability. ... get access to high-quality resources, while others seem ... the lower-quality resources that are left over for ... and human societies seems to fluctuate considerably over ...
Breaking Biology News(10 mins):Geneticist and humanitarian: Prof. Mary-Claire King receives Lasker Award 2A mechanism that allows a differentiated cell to reactivate as a stem cell revealed 2Evolution of competitiveness 2Evolution of competitiveness 3
... HOUSTON (Dec. 5, 2013) A new method ... proteins may speed the process of novel drug design, ... combination of computational techniques and experimental data helped Rice ... have been hard to detect. The work ...
... CHAMPAIGN, Ill. A 115-million-year-old fossilized wasp from northeast Brazil ... organ through which it lays its eggs, looks a lot ... figs. The problem, researchers say, is that figs arose about ... report of the findings appears in the journal ...
... levers: miniaturized robots of the future will be "soft". , ... to mind are the tentacles of an octopus or the ... a crane or the inner workings of a watch. And ... organisms moving in water. The robots of the future will ...
Cached Biology News:Proteins' passing phases revealed 2Proteins' passing phases revealed 3Ancient 'fig wasp' lived tens of millions of years before figs 2'Soft' (and miniaturized) robots 2
... the ideal CO2 incubator for cell and ... embryos at or near body temperature. HERAcell ... needed to protect and grow your valuable ... incubation conditions ensure optimum culture growth. ...
SP6 RNA Polymerase, 50 l, 20 U/l ,Cap Scribe Buffer, 100 l, 5x conc....
...
... High Vacuum pumps deliver critical performance ... gas ballast control optimizes pump performance to ... glass allows for convenient checking of proper ... series of pumps is designed to work ...
Biology Products: